Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0YA0N
|
|||
| Former ID |
DCL000729
|
|||
| Drug Name |
BR3-Fc
|
|||
| Indication | Idiopathic thrombocytopenic purpura [ICD-11: 3B64.10; ICD-10: D69, D69.3] | Discontinued in Phase 2 | [1] | |
| Rheumatoid arthritis [ICD-11: FA20] | Discontinued in Phase 2 | [1] | ||
| Company |
Genentech; Biogen Idec
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B-cell-activating factor (TNFSF13B) | Target Info | Inhibitor | [1], [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| NF-kappa B signaling pathway | ||||
| Intestinal immune network for IgA production | ||||
| Rheumatoid arthritis | ||||
| Reactome | TNFR2 non-canonical NF-kB pathway | |||
| TNFs bind their physiological receptors | ||||
| TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway | ||||
| WikiPathways | Spinal Cord Injury | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Emerging drugs for idiopathic thrombocytopenic purpura in adults. Expert Opin Emerg Drugs. 2008 Jun;13(2):237-54. | |||
| REF 2 | Emerging drugs for rheumatoid arthritis. Expert Opin Emerg Drugs. 2008 Mar;13(1):175-96. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.